LHCGR: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of LHCGR. The page also collects GeneMedi's different modalities and formats products for LHCGR in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the LHCGR target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
This gene encodes the receptor for both luteinizing hormone and choriogonadotropin. This receptor belongs to the G-protein coupled receptor 1 family, and its activity is mediated by G proteins which activate adenylate cyclase. Mutations in this gene result in disorders of male secondary sexual character development, including familial male precocious puberty, also known as testotoxicosis, hypogonadotropic hypogonadism, Leydig cell adenoma with precocious puberty, and male pseudohermaphtoditism with Leydig cell hypoplasia. [provided by RefSeq, Jul 2008]
|Gene Official Name||LHCGR|
|Gene Alias||HHG, LCGR, LGR2, LH/CG-R, LH/CGR, LHR, LHRHR, LSH-R, ULG5|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index|
Pre-made LHCGR-specific INN-index biosimilar (antibody&conjugates)-choriogonadotropin beta
Anti-LHCGR therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-INN-778||Pre-Made Choriogonadotropin Beta Biosimilar, Recombinant Protein targeting LHCGR: Recombinant therapeutic protein targeting HHG/LCGR/LGR2/LH/CG-R/LH/CGR/LHR/LHRHR/LSH-R/ULG5||choriogonadotropin beta||LHCGR||Recombinant Protein|
Pre-made anti-LHCGR inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-LHCGR benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-LHCGR mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T79473-Ab||Anti-LHCGR monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody|